Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

被引：0

作者：

Kelly, Karen

Mazieres, Julien

Leighl, Natasha B.

Barlesi, Fabrice

Zalcman, Gerard

Gordon, Michael S.

Reckamp, Karen L.

Gandara, David R.

Gomez-Roca, Carlos Alberto

Bennouna, Jaafar

Cho, Byoung Chul

Park, Keunchil

Infante, Jeffrey R.

Richards, Donald A.

Wu, Yuehui

Schramek, Daniel J.

Cox, Donna S.

Gardner, Olivia S.

Peddareddigari, Vijay Gopal Reddy

Blumenschein, George R.

机构：

[1] UC Davis Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA

[2] Hop Larrey CHU Toulouse, Toulouse, France

[3] Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Aix Marseille Univ, Hop Nord, Assistance Publ Hop Marseille, Marseille, France

[5] Caen Univ Hosp, Caen, France

[6] Pinnacle Oncol Hematol, Scottsdale, AZ USA

[7] City Hope Comprehens Canc Ctr, Duarte, CA USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[9] Inst Claudius Regaud, Toulouse, France

[10] Inst Cancerol Ouest, Nantes, France

[11] Yonsei Univ, Coll Med, Seoul, South Korea

[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[13] Sarah Cannon Res Inst, Nashville, TN USA

[14] Tennessee Oncol, Nashville, TN USA

[15] Texas Oncol, Houston, TX USA

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8027

引用

页数：1

共 50 条

[21] A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)
Camidge, D. Ross
Pachter, Jonathan
Koustenis, Andrew
Patrick, Gloria
Spigel, David R.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[22] Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)
von Itzstein, Mitchell S.
Burns, Timothy F.
Dowell, Jonathan
Horn, Leora
Camidge, David Ross
York, Sally J.
Eaton, Keith D.
Walker, Christopher James
Zhang, Song
Gerber, David E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer
von Itzstein, Mitchell S.
Burns, Timothy F.
Dowell, Jonathan E.
Horn, Leora
Camidge, D. Ross
York, Sally J.
Eaton, Keith D.
Kyle, Kelly
Fattah, Farjana
Liu, Jialiang
Mu-Mosley, Hong
Gupta, Arjun
Nadeem, Urooba
Gao, Ang
Zhang, Song
Gerber, David E.
CLINICAL CANCER RESEARCH, 2025, 31 (04) : 639 - 648
[24] First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC)
Mekhail, Tarek
Waterhouse, David Michael
Hadley, Terence J.
Webb, Charles D.
Burris, Howard A.
Hainsworth, John D.
Greco, F. Anthony
Spigel, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[25] A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
Planchard, David
Wolf, Juergen
Solomon, Benjamin
Sebastian, Martin
Wermke, Martin
Heist, Rebecca S.
Sun, Jong-Mu
Kim, Tae Min
Reguart, Noemi
Sanmamed, Miguel F.
Felip, Enriqueta
Garrido, Pilar
Santoro, Armando
Bootle, Douglas
Couillebault, Xuan-Mai
Gaur, Anil
Mueller, Christina
Poggio, Teresa
Yang, Jie
Moschetta, Michele
Dooms, Christophe
LUNG CANCER, 2024, 197
[26] Anti-tumor activity of a TBK1/IKBKE inhibitor in combination with a MEK inhibitor in KRAS mutant colorectal and non-small cell lung cancer models
Stinson, S.
He, J.
Hollenback, D.
Jia, J.
Kaplan, J.
Venkataramani, C.
Babusis, D.
Guevara, F.
Nelson, T.
Cavanaugh, J.
Asahina, H.
Ray, A.
Sicinska, E.
Fuchs, C.
Barbie, D.
Wong, K. K.
Ng, K.
Dornan, D.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S146 - S146
[27] Exploiting MCL1 Dependency with Combination MEK+MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer
Nangia, Varuna
Siddiqui, Faria M.
Caeriepeel, Sean
Timonina, Daria
Bilton, Samantha J.
Phan, Nicole
Gomez-Caraballo, Maria
Archibald, Hannah L.
Li, Chendi
Fraser, Cameron
Rigas, Diamanda
Vajda, Kristof
Ferris, Lorin A.
Lanuti, Michael
Wright, Cameron D.
Raskin, Kevin A.
Cahill, Daniel P.
Shin, John H.
Keyes, Colleen
Sequist, Lecia, V
Piotrowska, Zofia
Farago, Anna F.
Azzoli, Christopher G.
Gainor, Justin F.
Sarosiek, Kristopher A.
Brown, Sean P.
Coxon, Angela
Benes, Cyril H.
Hughes, Paul E.
Hata, Aaron N.
CANCER DISCOVERY, 2018, 8 (12) : 1598 - 1613
[28] Potent anti-tumor activity of the MEK1/2 inhibitor MEK162 in human non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) cell lines
Wong, Deborah J.
Garon, Edward B.
Silveira, Danielle D.
Kamranpour, Naeimeh
Pitts, Sharon
Chalukya, Meenal
Hamidi, Habib
Dubinett, Steven
Linnartz, Ronald
Finn, Richard S.
Slamon, Dennis J.
CANCER RESEARCH, 2014, 74 (19)
[29] Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type
Murakami, Shuji
Saito, Haruhiro
Kondo, Tetsuro
Oshita, Fumihiro
Yamada, Kouzo
JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, 2019, 13 (02) : 131 - 138
[30] A PHASE II STUDY OF PEMETREXED IN PS 2 PATIENTS WITH ADVANCED EGFR WILD-TYPE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Hata, Akito
Tanaka, Kosuke
Fujita, Shiro
Katakami, Nobuyuki
Kaneda, Toshihiko
Nishiyama, Akihiro
Nishimura, Takashi
Otsuka, Kojiro
Urata, Yoshiko
Negoro, Shunichi
ANNALS OF ONCOLOGY, 2014, 25

← 1 2 3 4 5 →